Skip to main content

뉴스

UCI MIND faculty finds connection between air pollution from traffic and Alzheimer’s disease

으로 회전식 슬라이더, 뉴스에서, UCI 마음

Masashi Kitazawa, Associate Professor of Environmental and Occupational Health, and his team found exposure to traffic-related air pollution led to memory loss and cognitive decline and triggered neurological pathways associated with the onset of Alzheimer’s disease. Read the article here.

게시물 UCI MIND faculty finds connection between air pollution from traffic and Alzheimer’s disease 에 처음 등장 UCI 마음.

더 읽어보기

And now, the FDA approves a medication for behavioral symptoms of Alzheimer’s disease

으로 회전식 슬라이더, 뉴스에서, UCI 마음

May 12, 2023–Brexpiprazole has now been approved by the FDA for the treatment of agitation in Alzheimer’s dementia.  Agitated behaviors are common in those with moderate or advanced Alzheimer’s dementia and these symptoms contribute substantially to caregiver burden, institutionalization, and faster cognitive decline.  Yesterday’s decision marks the first approval in the United States of a medication for these symptoms. The approval was based on the results of three 12-week treatment studies.  The studies collectively showed modest reduction in the frequency of specific agitated behaviors and lower severity on a clinician-rated measure.  In one of the studies, 56% of those treated…

게시물 And now, the FDA approves a medication for behavioral symptoms of Alzheimer’s disease 에 처음 등장 UCI 마음.

더 읽어보기

Positive topline results announced for TRAILBLAZER 3

으로 회전식 슬라이더, 뉴스에서, UCI 마음

May 3, 2023–Eli Lilly and company announced today (https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional) the positive topline results from their Phase 3 clinical trial of donanemab, a monoclonal antibody that rapidly lowers beta amyloid levels in the brain of people with Alzheimer’s disease. The release indicated that patients treated with donanemab experienced significantly slower cognitive and functional decline, compared to those receiving placebo, over 18 months. The primary outcome was a composite measure known as the integrated Alzheimer’s Disease Rating Scale (iADRS, a tool that borrows pieces of other instruments to look at elements key in early disease) and was reported as demonstrating a 35%…

게시물 Positive topline results announced for TRAILBLAZER 3 에 처음 등장 UCI 마음.

더 읽어보기

Dementia doubles in Orange County in less than a decade – UCI MIND Director weighs in

으로 회전식 슬라이더, 뉴스에서, UCI 마음

New number crunching from the Alzheimer’s Orange County estimates that the number of folks enduring this sort of heartbreak has essentially doubled since 2014 in the O.C. That’s a startling jump, from 84,000 to 164,000 people, which works out to about 5% of our total population. … “The new number is believable, especially if a difference from the previous estimate is the inclusion of mild cognitive impairment as a category,” said Dr. Joshua D. Grill, Professor of Neurobiology & Behavior and noted Alzheimer’s researcher at UC Irvine . “Orange County is ‘grayer’ than the rest of the country, so we do…

게시물 Dementia doubles in Orange County in less than a decade – UCI MIND Director weighs in 에 처음 등장 UCI 마음.

더 읽어보기

Annual Symposium Research Highlights

으로 뉴스에서, UCI 마음

On Monday, April 17th, 2023, the trainee led Research and Education in Memory Impairments and Neurological Disorders (REMIND) held its 14th annual Emerging Scientists Symposium.  The event is designed to help early career scientists share their research and network with colleagues and mentors.  Like previous years, this symposium included research talks from invited graduate and postdoctoral trainees, poster presentations, and a keynote presentation.  The REMIND co-chairs were honored this year to welcome Rema Raman, PhD, Professor of Neurology at the Keck School of Medicine at USC, to speak on “Advancing Alzheimer’s clinical trials through a convergence of statistics, machine learning and Al”.   Microglial replacement,…

게시물 Annual Symposium Research Highlights 에 처음 등장 UCI 마음.

더 읽어보기

UCI MIND faculty member speaks at local Alzheimer’s event

으로 회전식 슬라이더, 뉴스에서, UCI 마음

Dr. Frank LaFerla, Dean of the School of Biological Sciences and UCI MIND faculty member speaks at local educational event for the Alzheimer’s Foundation of America. Read about the event and the prevalence of Alzheimer’s disease in California here.

게시물 UCI MIND faculty member speaks at local Alzheimer’s event 에 처음 등장 UCI 마음.

더 읽어보기

UCI MIND faculty named one of the top inspirational Black women in medicine

으로 회전식 슬라이더, 해설, 뉴스에서, UCI 마음

UCI MIND faculty member and professor in the School of Public Health,  Karen D. Lincoln, PhD, MSW, MA, FGSA, is featured in Authority Magazine as being one of the top inspirational Black women in medicine. Read the full interview here To learn more about Dr. Lincoln’s research to address health disparities in Black communities, visit her faculty profile or her website: Advocates for African American Elders  

게시물 UCI MIND faculty named one of the top inspirational Black women in medicine 에 처음 등장 UCI 마음.

더 읽어보기

MIND Matters | Quarterly Newsletter | Winter 2023

으로 임상 시험, 해설, 커뮤니티 이벤트, COVID-19, 뉴스에서, Longitudinal Cohort, Participants, UCI 마음

Message from the Director Dear Friends of UCI MIND, Advances in the field of Alzheimer’s disease (AD) research and the contributions of UCI MIND investigators remain tremendously exciting. Two new drugs have been approved by the FDA (page 3). These approvals are believed by many to represent the dawn of a new age in AD research and treatment. Both drugs received accelerated approval and we await a decision from the FDA about “full approval” for lecanemab. If received, full approval could cause the Centers for Medicare and Medicaid Services to revisit their previous coverage decision about anti-amyloid antibody therapies. These…

게시물 MIND Matters | Quarterly Newsletter | Winter 2023 에 처음 등장 UCI 마음.

더 읽어보기

Inaugural Recipient of the UCI MIND Joan and Don Beall Scholar Award

으로 회전식 슬라이더, 뉴스에서, UCI 마음

The UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND) is pleased to announce that the inaugural recipient of the “UCI MIND Joan and Don Beall Scholar Award” is S. Ahmad Sajjadi, MD, PhD. Dr. Sajjadi is an Associate Professor of Neurology in the UCI School of Medicine. A clinician scientist with an established track record of studying different neurodegenerative pathologies across the aging spectrum, Dr. Sajjadi has demonstrated himself as an outstanding investigator and an important contributor to Alzheimer’s disease and related dementias (ADRD) research and clinical care at UCI. He is an investigator in the UCI Alzheimer’s…

게시물 Inaugural Recipient of the UCI MIND Joan and Don Beall Scholar Award 에 처음 등장 UCI 마음.

더 읽어보기

A4 Study Releases Negative Results

으로 회전식 슬라이더, 해설, 뉴스에서, UCI 마음

The topline results for the Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease (A4) study were released today (https://a4study.org). Unfortunately, the drug being investigated, solanezumab, failed to demonstrate a benefit in slowing memory changes in a population of individuals age 65-to-85 who met criteria for preclinical Alzheimer’s disease. Preclinical Alzheimer’s is a relatively new construct. It includes people who are older and have normal memory performance, but in whom biological tests suggest that the risk for Alzheimer’s disease dementia is high. The A4 study was among the first ever preclinical AD trials, boldly blazing a trail that has now been followed by…

게시물 A4 Study Releases Negative Results 에 처음 등장 UCI 마음.

더 읽어보기

UCI faculty member awarded grant to study patient reactions to Alzheimer’s disease diagnoses

으로 회전식 슬라이더, 뉴스에서, UCI 마음

Dr. Joshua Grill and colleagues at the University of Pittsburgh have been awarded a 3.5 million dollar grant by the National Institute on Aging to advance the field’s understanding of real-world patient and family member reactions to biomarker-informed Alzheimer’s disease and related disorders (ADRD) diagnoses and to provide critical information for directing post-diagnostic resources to monitor and support those most in need. Read the full news story about this important research here  

게시물 UCI faculty member awarded grant to study patient reactions to Alzheimer’s disease diagnoses 에 처음 등장 UCI 마음.

더 읽어보기

No change in coverage yet for monoclonal antibody treatments for Alzheimer’s disease

으로 회전식 슬라이더, 해설, 뉴스에서, UCI 마음

On February 17, 2023, a bipartisan group of Senators sent the Secretary of Health and Human Services, Javier Baccera, and the Administrator of the Centers for Medicare and Medicaid Services (CMS), Chiquita Brooks-LaSure, a letter requesting that CMS reconsider their decision to require Coverage with Evidence Determination (CED) that was levied after the accelerated approval of aducanumab. The letter followed a similar request from the Alzheimer’s Association, made in December 2022. The CED decision significantly limited access to aducanumab and other monoclonal antibodies (should they be approved), requiring that coverage would be granted only if Medicare beneficiaries were enrolled in…

게시물 No change in coverage yet for monoclonal antibody treatments for Alzheimer’s disease 에 처음 등장 UCI 마음.

더 읽어보기

The family of Bruce Willis shared that he has FTD, what’s that?

으로 회전식 슬라이더, 해설, 뉴스에서, UCI 마음

Frontotemporal dementia (FTD) is a form of dementia that typically affects individuals in their 50s and 60s. It is therefore, commonly referred to as young onset dementia. Clinically, FTD can present in two ways; some patients present with behavioral impairment and are referred to as behavioral variant FTD (bvFTD). The other main presentation involves language decline and is called primary progressive aphasia (PPA). Both conditions start insidiously and accurate diagnosis can be a challenge, especially at early stages of the disease. In bvFTD, patients can present with apathy, lack of empathy, increased appetite, preference for sweet tooth, new onset of…

게시물 The family of Bruce Willis shared that he has FTD, what’s that? 에 처음 등장 UCI 마음.

더 읽어보기

Support from Joan and Don Beall will sustain two UCI MIND programs

으로 회전식 슬라이더, 뉴스에서, UCI 마음

Irvine, Calif., Jan. 31, 2023 — Sustained support from philanthropists Joan and Don Beall to the the Institute for Memory Impairments and Neurological Disorders will allow for the continuation of an educational outreach program in Orange County high schools and the creation of a new research award for an early career researcher. “We are grateful for the Beall’s leadership, involvement and increased support of $100,000 a year for our educational and research programs,” said Joshua Grill, director of UCI MIND. “Support like theirs is critical to the institute’s mission and demonstrates the trust and commitment of the local community in…

게시물 Support from Joan and Don Beall will sustain two UCI MIND programs 에 처음 등장 UCI 마음.

더 읽어보기

UCI MIND Faculty leads study to model sporadic Alzheimer’s disease in degus

으로 회전식 슬라이더, 뉴스에서, UCI 마음

UCI School of Medicine highlighted innovative research performed in the lab of Xiangmin Xu, PhD, UCI MIND faculty member and professor and Chancellor’s Fellow of anatomy and neurobiology in the UCI School of Medicine.  Dr. Xu and colleagues have found that sporadic Alzheimer’s disease can be modeled in a non-murine rodent called the Chilean degu. “Our findings, taken together, show spontaneous AD-like correlative phenotypes in cognitive performance and neuropathology in aged, outbred degus. This supports that aged degus are a useful and practical model of natural sporadic AD.” Xiangmin Xu Read the article in the February edition of the UCI School…

게시물 UCI MIND Faculty leads study to model sporadic Alzheimer’s disease in degus 에 처음 등장 UCI 마음.

더 읽어보기

FDA decides not to grant accelerated approval to donanemab

으로 회전식 슬라이더, 해설, 뉴스에서, UCI 마음

In a somewhat surprising move, the US Food and Drug Administration (FDA) has declined to grant accelerated approval to Eli Lilly’s donanemab Read the full press release from Eli Lilly here Like aducanumab and lecanemab, which were previously granted accelerated approval by the FDA, donanemab is a monoclonal antibody treatment against the beta amyloid protein that accumulates in the brain of a person with Alzheimer’s disease. Eli Lilly published very promising results for donanemab in 2021, which included demonstration that donanemab could lower amyloid levels in the brain of people with mild cognitive impairment and mild dementia (the basis for…

게시물 FDA decides not to grant accelerated approval to donanemab 에 처음 등장 UCI 마음.

더 읽어보기
한국어